Enantiomer (-)-n-(2-ethoxyphenyl)-n'- (1,2,2-trimethylpropyl)-2-nitroethene-1-, 1-diamine, process for the preparation thereof and the use thereof
CA 2091634 A1 · Owner: Bayer Aktiengesellschaft · Inventors: Muschalek-Letina, Volker; Hunnicutt, Edward; Niemers, Ekkehard
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Enantiomer (-)-N-(2-ethoxyphenyl)-N'-(1,2,2-trimethylpropyl)-2-nitroethene-1-,1-diamine, process for the preparation thereof and the use thereof Abstract, The invention relates to the enantiomer (-)-N-(2-ethoxyphenyl)-N'-(1,2,2-trimethylpropyl)-2-nitroethene-1-,1-diamine, process for the preparation thereof and the use thereof as medicament influencing nervous and neuro/endocrine diseases including but not, limited to cerebral ischemia, excitatory injury stroke, dementias, and epilepsy. At higher concentrations, potential uses include angina hypertension, urinary incontinence, baldness asthma, peripheral vascular disease, cardiac disrythmia myocardial ischemia, sexual dysfunction and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 15, 1993. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 15, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 15, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.